Wk+11+CVR+Lesson+83+Lab+Evaluation+of+hemostasis-+In+class

Cardiorespiratory Laboratory Evaluation of Hemostasis - Part 1

Dr. India PaharsinghInstitution: St. George's University, School of Veterinary Medicine, Grenada, West Indies

Thrombocytopenia:
- Identify 4 causes of thrombocytopenia.
- Describe the pathogenesis of immune-mediated and consumptive thrombocytopenia and differentiate their clinical implications.
Thrombocytosis:
- Identify relevant clinical reasons and describe the pathogenesis for thrombocytosis including but not limited to inflammatory responses, iron deficiency, and exercise-induced thrombocytosis.
Primary Hemostatic Defects:
- Identify the top 3 differentials for primary hemostatic defects, understanding the underlying mechanisms and impacts on the patient.

Decreased Production:
- Bone Marrow Disease: Conditions such as aplastic anemia or neoplastic infiltration can significantly reduce the production of platelets.
- Drug Effects: Certain medications, especially chemotherapy agents, can lead to suppression of the bone marrow, reducing platelet production.
- Viral Infections: Infections like BVD (Bovine Viral Diarrhea), canine distemper, and Parvovirus can affect bone marrow and lead to lower platelet counts.
- Toxins: Exposure to certain toxins, such as estrogen or bracken fern, can have detrimental effects on platelet production.
Increased Destruction:
- Immune-Mediated Mechanisms: The formation of anti-platelet antibodies can lead to destruction of platelets, commonly seen in conditions such as immune thrombocytopenia.
- Idiopathic Thrombocytopenia: This condition arises without identifiable cause and denotes a serious risk to patient health.
- Infectious Causes: Certain infections, e.g., Anaplasma platys, can mediate platelet destruction.
Sequestration:
- This involves the pooling of platelets as a result of conditions like splenomegaly or endotoxemia, where the spleen sequesters an increased number of platelets, leading to lower circulating levels.
Consumption:
- Conditions such as DIC (Disseminated Intravascular Coagulation), where there is extensive thrombosis and platelet usage, or vasculitis, can result in rapid consumption of platelets.

Initial Assessment: Start with a blood smear evaluation to assess for signs of thrombopoiesis, such as the presence of large platelets, which can indicate regeneration.
Bone Marrow Aspirate: To confirm suspicion of marrow disease, bone marrow samples may be taken to assess the hematopoietic activity, cellularity, and presence of abnormal cells.

Pseudothrombocytopenia: This condition may arise due to platelet clumping typically seen in certain species like cats, or the presence of giant platelets causing misleadingly low counts.
True Thrombocytopenia: Proper diagnosis requires confirming tests indicating that the platelet count is critically low and not an artifact from the testing process.

Thrombocytosis: Defined as a platelet count exceeding the upper reference limit. It can be categorized as either primary (often due to clonal processes in the bone marrow) or secondary/reactive, resulting from various physiological or pathological stimuli.

Primary Thrombocytosis: Generally rare but may occur in cases involving hemic neoplasia, such as acute megakaryoblastic leukemia.
Secondary (Reactive) Thrombocytosis: Can be due to inflammation, iron deficiency, or following recovery from a state of thrombocytopenia.

Redistribution: This occurs when physical stressors (e.g., exercise, epinephrine release) cause transient increases in platelets.
Increased Production: This is triggered by ongoing inflammatory processes, due to infections, or as a response to iron deficiency.

Primary Hemostasis: Involves the formation of a platelet plug, which is critical to stanching bleeding immediately after vascular injury.
Secondary Hemostasis: Involves the activation of coagulation factors leading to the formation of a stable fibrin clot.
Tertiary Hemostasis: Represents the process of fibrinolysis, ultimately resulting in the dissolution of the clot to restore normal blood flow.

Platelets: Central to primary hemostasis involved in adhesion to injury sites and aggregation.
Coagulation Factors: Proteins crucial for secondary hemostasis; for instance, Thrombin acts to convert fibrinogen into fibrin.
Plasmin and t-PA: Key enzymes in the clot dissolution pathway, necessary for controlling hemostatic processes.

Primary Hemostatic Disorders: Often manifest as petechiae (small red or purple spots due to bleeding), and mucosal bleeding which indicates inadequate platelet function or number.
Secondary Hemostatic Disorders: Typically present with larger hematomas, cavity bleeding such as hemoabdomen, and frank hemorrhage, indicating issues with coagulation factors rather than platelets.

Common Considerations: Include thrombocytopenia, von Willebrand disease (vWD), and abnormalities in platelet function, including receptor deficiencies or disorders affecting platelet aggregation.

Complete Blood Count (CBC): Initial screening tool to evaluate platelet counts and help rule out common causes of bleeding disorders.
Follow-up Tests: Depending on results, tests like von Willebrand factor assays and detailed platelet function tests can help refine the diagnosis and management strategies.

Severe thrombocytopenia (<20,000/µL) can lead to spontaneous hemorrhage, which is a critical condition needing rapid medical intervention.
Understanding both the causes and mechanisms of thrombocytopenia and thrombocytosis is imperative for proper diagnosis and effective management of hemostatic disorders.
Recognizing significant clinical signs can aid in distinguishing between defects in primary versus secondary hemostasis, directing appropriate follow-up testing and management strategies.